Patents Assigned to THE SECOND MILITARY MEDICAL UNIVERSITY
-
Patent number: 11124832Abstract: A serum microRNA (miRNA) marker suitable for early screening and diagnosis of ossification of posterior longitudinal ligament (OPLL) and its application in the diagnostic reagent or kit for the OPLL. Biomarker miRNA-563, miRNA-196b, miRNA-10a and miRNA-129 have high diagnostic value for OPLL, and the development and application of the related serum miRNA biomarker detection reagent kit. It can be applied in the screening of ossification of posterior longitudinal ligament disease, supporting the diagnosis of OPLL more quickly and accurately, evaluate the patient's ossification condition, and may lay down the foundation for improving clinical therapeutic effect.Type: GrantFiled: December 7, 2016Date of Patent: September 21, 2021Assignee: THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Yang Liu, Chen Xu, Hao Zhang, Wen Yuan, Peng Cao, Huiqiao Wu, Yuanyuan Chen, Xiaolong Shen
-
Patent number: 11007047Abstract: An endoleak preventing stent graft system, used for preventing the endoleaks except for type II endoleak, comprising: a metal mesh support layer fit for the shape of the artery blood vessel; a cover film layer covering on said metal mesh support layer; and a flexible mesh layer covering outside said cover film layer, said flexible mesh layer fills up the gap formed between said cover film layer and the inwall of said artery blood vessel under the effect of the flexibility of itself.Type: GrantFiled: December 18, 2015Date of Patent: May 18, 2021Assignee: THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Junmin Bao, Jian Dong, Liangxi Yuan, Yanchun Meng, Jian Zhou, Zaiping Jing
-
Patent number: 10323244Abstract: Provided are an LncRNA and oncolytic adenovirus, and application thereof. The oncolytic adenovirus is used as a carrier to express the LncRNA, so as to express the LncRNA in a cancer cell; competitively binding a target gene of OncomiRs, and consuming the OncomiRs, thus protecting a cancer suppressor gene from interference and suppression of the OncomiRs, and achieving target intervention therapy of the cancer cell.Type: GrantFiled: October 14, 2015Date of Patent: June 18, 2019Assignee: SECOND MILITARY MEDICAL UNIVERSITY OF THE PEOPLE'S LIBERATION ARMYInventors: Changqing Su, Yinghan Su, Xiaoya Li, Weidan Ji, Kouyong Liu
-
Publication number: 20170314018Abstract: Provided are an LncRNA and oncolytic adenovirus, and application thereof. The oncolytic adenovirus is used as a carrier to express the LncRNA, so as to express the LncRNA in a cancer cell; competitively binding a target gene of OncomiRs, and consuming the OncomiRs, thus protecting a cancer suppressor gene from interference and suppression of the OncomiRs, and achieving target intervention therapy of the cancer cell.Type: ApplicationFiled: October 14, 2015Publication date: November 2, 2017Applicant: SECOND MILITARY MEDICAL UNIVERSITY OF THE PEOPLE'S LIBERATION ARMYInventors: Changqing Su, Yinghan Su, Xiaoya Li, Weidan Ji, Kouyong Liu
-
Patent number: 9386762Abstract: Provided is a renal sarcomatoid cell line RCC09HYF, of which the deposit No. is CCTCC C201130, and the preparation method of the renal sarcomatoid cell line. The renal sarcomatoid cell line RCC09HYF can grow for a long period and be steadily passaged in vitro. By tumorigenic experiments using in-situ animal models in vitro it has been found that: the tumorigenesis is relatively fast inside animals and 3-4 weeks after tumor inoculation, the transplanted tumors fill the whole abdominal cavity, and dyscrasia appears in above 50% of nude mice; moreover, lung metastasis is present in a few individuals. The renal sarcomatoid cell line RCC09HYF can provide an effective and steady cell model for further study of the genesis and metastasis mechanism of renal sarcomatoid carcinoma in persons of Han nationality and for clinical prediction, diagnosis and treatment.Type: GrantFiled: July 19, 2012Date of Patent: July 12, 2016Assignee: SECOND MILITARY MEDICAL UNIVERSITYInventors: Xiaojie Tan, Yifang Han, Wei Guan, Wenjun Chang, Guangwen Cao
-
Publication number: 20160083347Abstract: The present invention discloses a class of mercaptonicotinic acid compound and preparation method and use thereof; the general structural formula of the compound is as shown in Formula I. Experiment demonstrates that the mercaptonicotinic acid compound could inhibit activity of botulinum toxin endopeptidase and tetanus toxin endopeptidase in vitro, which has a significant protective effect on botulinum toxin poisoning in mice, and can be used for preparing medicine intended to prevent and/or treat botulism, as well as to prevent botulinum toxin exposure and tetanus.Type: ApplicationFiled: May 19, 2014Publication date: March 24, 2016Applicants: INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PR CHINA, THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Hui WANG, Wannian ZHNG, Zhenyuan MIAO, Tao LI, Xiong LIU, Yuelin WU, Sen LUO, Chunquan SHENG, Xiaoxue LU, Jianzhong YAO
-
Patent number: 9273127Abstract: The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28GANK. The invention also provides the monoclonal antibodies against human p28GANK and their use.Type: GrantFiled: December 9, 2011Date of Patent: March 1, 2016Assignee: The Second Military Medical University, The People's Liberation ArmyInventors: Hongyang Wang, Yao Chen, Jing Fu, Dongping Hu, Tao Luo, Liwei Dong
-
Patent number: 9181193Abstract: An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.Type: GrantFiled: May 17, 2011Date of Patent: November 10, 2015Assignee: Second Military Medical University, PLAInventors: Yunlong Song, Xiaodan Fu, Yunpeng Qi, Yves G. Pommier
-
Publication number: 20150135342Abstract: Provided is a renal sarcomatoid cell line RCC09HYF, of which the deposit No. is CCTCC C201130, and the preparation method of the renal sarcomatoid cell line. The renal sarcomatoid cell line RCC09HYF can grow for a long period and be steadily passaged in vitro. By tumorigenic experiments using in-situ animal models in vitro it has been found that: the tumorigenesis is relatively fast inside animals and 3-4 weeks after tumor inoculation, the transplanted tumors fill the whole abdominal cavity, and dyscrasia appears in above 50% of nude mice; moreover, lung metastasis is present in a few individuals. The renal sarcomatoid cell line RCC09HYF can provide an effective and steady cell model for further study of the genesis and metastasis mechanism of renal sarcomatoid carcinoma in persons of Han nationality and for clinical prediction, diagnosis and treatment.Type: ApplicationFiled: July 19, 2012Publication date: May 14, 2015Applicant: SECOND MILITARY MEDICAL UNIVERSITYInventors: Xiaojie Tan, Yifang Han, Wei Guan, Wenjun Chang, Guangwen Cao
-
Patent number: 8846627Abstract: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.Type: GrantFiled: April 23, 2012Date of Patent: September 30, 2014Assignees: The Second Military Medical University, East China University of Science and TechnologyInventors: Weidong Zhang, Jin Huang, Lei Shan, Honglin Li, Liyan Wang, Shoude Zhang, Weiqiang Lu, Juan Su, Tong Chen
-
Publication number: 20140010786Abstract: A use of a hepatocyte nuclear factor 1? gene and/or protein and a recombinant expression vector containing a hepatocyte nuclear factor 1? in preparation of drugs for treating malignant solid tumor diseases and in preparation of differentiation inducing reagents or composition for inducing differentiation of malignant solid tumor cells. The hepatocyte nuclear factor 1? gene can improve the biological properties of tumor cells, and retard the growth of tumor cells, and up-regulation of expression thereof has therapeutic effects on animal models with malignant solid tumors.Type: ApplicationFiled: October 24, 2011Publication date: January 9, 2014Applicant: SECOND MILITARY MEDICAL UNIVERSITY OF THE PEOPLE'S LIBERATION ARMYInventors: Weifen Xie, Xin Zeng, Yong Lin
-
Publication number: 20130337467Abstract: The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28GANK. The invention also provides the monoclonal antibodies against human p28GANK and their use.Type: ApplicationFiled: December 9, 2011Publication date: December 19, 2013Applicant: The Second Military Medical University, The People's Liberation ArmyInventors: Hongyang Wang, Yao Chen, Jing Fu, Dongping Hu, Tao Luo, Liwei Dong
-
Publication number: 20130102598Abstract: An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.Type: ApplicationFiled: May 17, 2011Publication date: April 25, 2013Applicant: SECOND MILITARY MEDICAL UNIVERSITY, PLAInventors: Yunlong Song, Xiaodan Fu, Yunpeng Qi
-
Publication number: 20120328588Abstract: A compound preparation contains alpha-lipoic acid and nimodipine at a ratio from 5:1 to 40:1. The above-mentioned compound preparation can be used for the prevention and treatment of noise-induced hearing impairment. This compound preparation not only increases the efficacy but decreases the dosage of nimodipine, reduces the side effects and improves the patient compliance.Type: ApplicationFiled: May 8, 2011Publication date: December 27, 2012Applicant: The Second Military Medical University of Chinese PLAInventors: Shen Gao, Jing Gao, Quangang Zhu, Xiying Wang, Xueying Ding, Wei Zhang, Xiaoyu Wang, Min Zhang, Xin Wu, Lihua Ye
-
Publication number: 20120295859Abstract: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.Type: ApplicationFiled: April 23, 2012Publication date: November 22, 2012Applicants: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY, THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Weidong ZHANG, Jin HUANG, Lei SHAN, Honglin LI, Liyan WANG, Shoude ZHANG, Weiqiang LU, Juan SU, Tong CHEN
-
Publication number: 20120122786Abstract: Use of polypeptide micromolecule MLIF in preparing medicine for preventing and treating myocardial ischmia, where amino acid sequence of the polypeptide micromolecule MLIF is Met-Gln-Cys-Asn-Ser (SEQ ID NO:1).Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Applicant: THE SECOND MILITARY MEDICAL UNIVERSITY, PLAInventors: Yaocheng Rui, Tiejun Li, Pengyuan Yang, Yuefan Zhang
-
Publication number: 20110077206Abstract: Use of hepatocyte nuclear factor 4? (HNF4?) for the treatment of human malignant solid tumors through induction-differentiation therapy is provided.Type: ApplicationFiled: April 30, 2009Publication date: March 31, 2011Applicant: SECOND MILITARY MEDICAL UNIVERSITYInventors: Weifen Xie, Chuan Yin, Yong Lin, Yuexiang Chen, Xin Zeng
-
Publication number: 20100030127Abstract: A duct stent being capable of carrying the subminiature radioactive particle source is mainly used for the inside radiation therapy of metaphase or terminal pancreatic cancer and bile duct cancer, and has drainage function. The duct stent consists of a tubular drainage tube (1) and fixation portions (2) which are face to face with two ends of the drainage tube (1) and can fix the stent to prevent the stent from moving. The lumen of the drainage tube (1) is a drainage cavity (1.1) for draining the pancreatic juice or the bile. A particle passage (1.2) is provided in the tube wall of the drainage tube (1). The inside diameter of the particle passage (1.2) matches with the outer diameter of the subminiature radioactive particle source.Type: ApplicationFiled: August 31, 2006Publication date: February 4, 2010Applicant: THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Yan Liu, Zheng Lu, Zhao-shen Li
-
Publication number: 20090170930Abstract: A method for promoting differentiation of clonogenic neural stem cells (NSCs), comprising administering to a patient in the need of such promoting a coumarin compound represented by formula I or by formula II. The representative coumarin compounds include 7-hydroxycoumarin, daphnoretin, scopoletin, edgeworin, aesculetin and esculetin-6-?-D-glucopyranoside. The coumarin compounds showed significant activity of directing the differentiation of NSCs in pharmacological test and thereof could be used to prepare drugs to direct NSCs differentiated to oligodendrocyte progenitor cells (OPCs) for the treatment of demyelinating diseases or spinal cord injury. The drug could be a pure coumarin compound or a pharmaceutical composition comprising a therapeutical dose of a coumarin compound as active ingredients and a pharmaceutically-acceptable carrier. The content of the active ingredients in the pharmaceutical composition is between 0.1% and 99.5% by weight.Type: ApplicationFiled: March 9, 2009Publication date: July 2, 2009Applicant: THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Cheng HE, Weidong ZHANG, Xiaohui XU, Wei ZHANG, Juan SU, Chuan ZHANG
-
Patent number: 7101556Abstract: The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1/MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.Type: GrantFiled: February 1, 2002Date of Patent: September 5, 2006Assignee: Second Military Medical UniversityInventor: Weiqing Pan